Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
71 72 Next >
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years
These stocks are potential bargain buys for investors right now, just waiting to get scooped up. 
Via The Motley Fool
The 3 Best Defensive Stocks for Nervous Investors
The best defensive stocks are especially worth considering at the moment as volatility spikes and confidence wavers. 
Via InvestorPlace
AbbVie Stock Moves Higher With Rising Relative Strength
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. Will it continue? 
Via Investor's Business Daily
3 Dividend Kings Every Investor Should Own to Survive a Market Crash
Dividend stocks that raise their payout beat all other kinds of stocks, making Dividend Kings the best stocks to buy in a downturn. 
Via InvestorPlace
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
AbbVie Unusual Options Activity
Via Benzinga
Should You Load Up On This 1 Dividend Stock?
It's not that hard a call. 
Via The Motley Fool
Check Out What Whales Are Doing With ABBV
Via Benzinga
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
These two healthcare stocks are reliable passive income vehicles. 
Via The Motley Fool
Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream
These dividend aristocrats are some of the best options for long-term investors looking to boost their portfolio return. 
Via InvestorPlace
Topics Retirement
Exposures Pension
7 Top Healthcare Stocks That Pay Dividends
With uncertainty being the dominant theme of the moment, investors should consider healthcare stocks that pay dividends. 
Via InvestorPlace
3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years
These are relatively safe income investments that you can hold on to for the long haul. 
Via The Motley Fool
3 Top Stocks to Buy in October and Hold Forever
Check out these three blue chip buys playing crucial roles in America's $6 trillion healthcare opportunity. 
Via The Motley Fool
What 4 Analyst Ratings Have To Say About AbbVie
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
How Is The Market Feeling About AbbVie?
Via Benzinga
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
These defensive index funds can help investors hedge against a possible recession. 
Via The Motley Fool
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
3 Magnificent Dividend Stocks to Buy in October
These stocks come with great dividends and more. 
Via The Motley Fool
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
Raymond James initiated coverage on AbbVie Inc (NYSE: ABBV) as the company looks beyond Humira's loss of exclusivity and has several levers to set up long-term growth. 
Via Benzinga
AbbVie's Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients
AbbVie Inc (NASDAQ: ABBV) released data from its Phase 3 CANOVA study evaluating venetoclax (Venclexta/ Venclyxto) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years
A basket of passive income opportunities in oil and gas, renewable energy, and healthcare. 
Via The Motley Fool
Three Of Our Top Picks For Your Healthcare Portfolio
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio. 
Via InvestorPlace
Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend
The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend. 
Via MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback